IDELVION offers powerful bleed protection
IN PROPHYLAXIS: IDELVION delivers zero bleeds regardless of dosing schedule
When dosed every 7 or 14 days, IDELVION had a zero median annualized spontaneous bleeding rate (AsBR).
When dosed at 14 days, IDELVION had an interquartile range, or IQR, of 0 to 1 bleed (IQR at 7 days was 0 to 0). IQR looks at the middle 50% of people in a clinical study and is used as a more accurate measure of expected range.
ON DEMAND: A single dose effectively treats bleeds and offers extended protection—high and sustained Factor IX (FIX) levels for more than 14 days1
A majority of bleeds resolved within 1–2 infusions:
- 94% of bleeds resolved within 1 infusion
- 99% of bleeds resolved within 1–2 infusions
IN SURGERY: IDELVION offers effective bleed protection
of rated surgeries were graded as “excellent” or “good” for bleed control three days after surgery
*Average FIX levels with 7-day dosing over 92 weeks in clincal trials.
References: 1. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. doi:10.1182/blood-2012-05-429688. 2. Data on file. Available from CSL Behring as DOF IDL-002.